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a b s t r a c t
Magnetic resonance imaging (MRI) contrast agents based on paramagnetic gadolinium complexes
are widely used in biomedical research and diagnosis. Their application is intended to improve efﬁ-
cacy of MRI providing physiological information along with the impressive anatomical detail already
obtained by images without contrast. The classical gadolinium complexes currently used for MRI con-
trast enhancement are all low molecular weight compounds that rapidly equilibrate between the intra and
extravascular spaces after intravenous administration. In order to obtain gadolinium-based agents with
different pharmacokinetic properties, supramolecular aggregates such as micelles and liposomes have
been recently proposed. Micelles and liposomes, obtained by the aggregation of lipophilic gadolinium
complexes are here described, with the aim to correlate their structural and relaxometric properties. Wearget-selective contrast agents report on the state of the art in the development of supramolecular aggregates obtained by self-assembly
of lipophilic gadolinium complexes and aggregates in which lipophilic gadolinium complexes are assem-
bled with surfactants. Moreover aggregates derivatized with bioactive molecules, such as peptides and
t sel
mportant contributes to the observed relaxivity and are known
s the inner-sphere relaxation rate and outer-sphere relaxation
ate, respectively. In addition, water molecules may be retained in
he periphery of the metal center by hydrogen bonds for a rela-ective MRI contrast agents are described.
© 2009 Elsevier B.V. All rights reserved.
tively long time without binding to the metal, this is known as the
second-sphere relaxation effect [8–11]. The overall measured relax-
ivity (Robs1 ) is, thus, a result of different contributions as indicated
by:
Robs1 = RIS1p + ROS1p + RW1 (1)
where RIS1p and R
OS
1p are the inner-sphere and outer-sphere relax-
ation enhancement in the presence of the paramagnetic complex
at 1 mM concentration, respectively, and RW1 is the relaxation rate
of the water solvent in the absence of the paramagnetic complex.
The four most important classical, clinically used, T1-agents
have a molecular weight around 600–700 Da and relaxivi-
ties between 4 and 5 mM−1 s−1 at 20 MHz and 310 K (Fig. 1).
They are based on chelating agents with a branched or cyclic
structure such as diethylenetriaminepentaacetic acid (DTPA)
or 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid (DOTA),
respectively. These CA are regarded as non-speciﬁc agents or
extracellular ﬂuid space (EFS) agents, they have very similar phar-
macokinetic properties because they distribute in the extracellular
ﬂuid and are eliminated via glomerular ﬁltration. They are particu-
larly useful to delineate lesions in the brain as a result of disruption
of the blood–brain barrier. Successively, two other derivatives
of Gd-DTPA were introduced [12,13] (Fig. 2). These compounds
feature increased lipophilicity due to the introduction of an aro-
matic substituent on the carbon backbone of the DTPA ligand.
This modiﬁcation signiﬁcantly alters the pharmacokinetics and
the biodistribution of these CA as compared to the parent com-
pound, Gd-DTPA. These hepatobiliary agents have afﬁnity towards
human serum albumin and are speciﬁcially concentrated by hepa-
tocytes. They are partially excreted through the biliary system and
the kidneys. By comparing the structure of hepatic agents with
that of EFS agents, the liver speciﬁcity can be ascribed to the pen-
dent hydrophobic phenyl rings. These small molecular contrast
agents have a major role in diagnostic imaging: they have promis-
ing targeting ability, diffusion and penetration and relaxivity that
can be modiﬁed according to different physiological states. How-
ever, the relaxivity and the speciﬁcity of these agents are limited;
hence, methods to increase their sensitivity and their targeting
ability have to be employed. To cope with the surging demand
for contrast agents in molecular imaging, tailor-made chelates are
required to improve relaxivity through the modulation of the coor-
dination environment around the Gd(III) center and, at the same
time, to increase the speciﬁcity for the in vivo micro-environmentantibodies, acting as targe
1. Introduction
Magnetic resonance imaging (MRI) is one of the most impres-
sive non-invasive medical diagnostic imaging procedure currently
in use. MRI is based on the same principles of nuclear magnetic res-
onance (NMR). It is based on the NMR signal generated by hydrogen
nuclei present in water and its changes that are dependent on the
chemical environment [1,2].
The use of a contrast agent (CA) in magnetic resonance imaging is
aimed at improving diagnostic accuracy of these clinical studies by
providing images that contain physiological information along with
the exquisitely high anatomic detail commonly obtained in non-
contrast-enhanced images [3,4]. Image contrast in MRI is related to
the relaxation process of hydrogen nuclei of water molecules. It is
governed by three parameters: proton density, longitudinal relax-
ation time T1, and transverse relaxation time T2. The variation in
the proton density between tissues is small; therefore, most of the
contrast measured in MRI images is based on the T1 or T2 relax-
ation times. Accordingly, pulse sequences are designed to obtain
distribution maps that are representative of one of the two param-
eters and are commonly referred to as T1- or T2-weighted images.
Contrast agents have been developed that can inﬂuence either of
these relaxation rates in tissues and are commonly referred to as
T1-agents and the T2-agents. The T1-agents, commonly based on
paramagnetic ions such as gadolinium(III) complexes, reduce the
longitudinal relaxation time and increase the T1 signal intensity giv-
ing a positive contrast [5]. Superparamagnetic compounds based on
iron oxide (SPIO) are T2-agents, they provide a negative contrast by
decreasing T2 signal intensity [6].
Relaxivity (r1) describes the efﬁcacy of the paramagnetic con-
trast agent, at 1 mM concentration, in changing the rate of water
proton relaxation [7]. The relaxation is due to dipole–dipole inter-
actions between the proton nuclear spins and the ﬂuctuating local
magnetic ﬁeld that results from the paramagnetic metal center.
The most common paramagnetic compounds are based on gadolin-
ium complexes coordinated by chelating agents. The gadolinium
atom has a high spin state due to seven unpaired electrons, more-
over, the coordinating agents leave one or two free positions for
water coordination in the nine-position coordination sphere of the
gadolinium ion. Water molecules that are coordinated to the metal
center give a direct contribution to relaxivity, while the bulk solvent
molecules experience the paramagnetic effect when they diffuse
around the metal center. These two interactions give the mostand for selected tissues or cells [14]. For example, the effective-
ness of Gd(III) complexes as CA may be signiﬁcantly improved
by using protein–chelate conjugates in which the metal complex
is covalently attached to amino acid residues of the protein [15],
A. Accardo et al. / Coordination Chemistry Reviews 253 (2009) 2193–2213 2195
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r by non-covalent binding of the complex to macromolecules
16]. This kind of approach allows one to couple the strong
helation of the metal ion with the slow molecular tumbling of
acromolecules. According to the Solomon–Bloembergen–Morgan
heory, an optimization of the water exchange rate, rotation
nd electronic paramagnetic relaxation, allows one to obtain a
elaxivity of 100 mM−1 s−1 for a complex with q = 1 at 20 MHz
11].
The research is now aimed in the development of new classes
f contrast agents with improved properties such as smart con-
rast agents, target selective contrast agents and multimeric or
acromolecular contrast agents [17,18]. “Smart or responsive con-
rast agents” are contrast agents in which a change in relaxivity is
bserved upon activation in the in vivo environment where they
ct [19]. They react to variables in their environment, such as tem-
erature [20], pH [21–23], partial pressure of oxygen [24,25], metal
on concentration [26] or enzyme activity [27,28], giving a strong
ncrease or decrease of the observed relaxivity. They are also used
s tumour selective contrast agents for their responsive ability to
umour cell environment characterized by lower pH or by presence
f different amounts of enzymes and proteins with respect to non-
athological environments. “Target selective contrast agents” are
ontrast agents in which the gadolinium complex is delivered in a
elective way on cells or tissues of interest by bioactive molecules
uch as peptides and antibodies; in this approach the presence
f speciﬁc receptors or membrane proteins overexpressed by can-
er cells is the molecular target where the gadolinium complexes
Fig. 2. Structures of two hepatobiliary agents which present pendent hydrophobic pagents currently used in the clinical practice.
derivatized with peptides or antibodies are intended to accumulate
[29,30].
In this review we will survey the MRI multimeric or macro-
molecular contrast agents in which a large number of gadolinium
complexes are combined toghether and the total relaxivity results
from the single contribution of each gadolinium ion [31,32].
We have devoted more attention to supramolecular aggregates,
such as micelles and liposomes, attempting to suggest how to form
aggregates with high relaxivity and stability. In particular in chap-
ter four we will describe the three classes of non-speciﬁc contrast
agents: (i) aggregates obtained directly by the self-assembly of
amphiphilic chelating agents, (ii) mixed aggregates containing syn-
thetic amphiphilic chelating agents and one or more commercial
phospholipids, and (iii) self-assembling aggregates of polymeric
amphiphiles that incorporate contrast agents. Finally in the ﬁfth
chapter we will evaluate target selective supramolecular aggre-
gates, in which peptides or antibodies are present on the external
surface of the aggregate for targeting molecules of biological inter-
est expressed on the cell surface.
2. Multimeric or macromolecular contrast agentsThe classical gadolinium complexes, currently available on the
market, are all low molecular weight compounds that rapidly
equilibrate between the intra and extravascular spaces after intra-
venous administration. In magnetic resonance angiography (MRA),
intravascular contrast agents are utilized for applications such as
henyl ring as aromatic substituent on the carbon backbone of the DTPA ligand.
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Fig. 3. Schematic representation of macromolecular adducts: (a) ramiﬁed or linear
polymers; (b) carbon nanostructures (fullurenes and nanotubes) externally deriva-
tized by stable gadolinium complexes; (c) macromolecular adducts obtained by196 A. Accardo et al. / Coordination Ch
oronary artery imaging [33,34] or for the assessment of other
mportant features such as: relative blood volume of tissues, rel-
tive blood ﬂow and endothelial permeability [35]. In fact, MRA
s the technique in which blood vessels are imaged by magnetic
esonance. Contrast-enhanced MRA provides a fast, reliable, non-
nvasive method for imaging large vascular structures, allowing one
o evaluate pulmonary blood supply in patients with complex pul-
onary stenosis and atresia, visualization and determination of the
atency of coronary bypass grafts and renal artery stenosis, both in
he native and in the transplanted kidney. In order to obtain a long
esidence time in blood of a gadolinium complex and increase the
otal relaxivity of the contrast agent, macromolecular and multi-
eric gadolinium complexes have been proposed so far.
A promising strategy is the insertion in the gadolinium complex,
f a substituent capable of binding serum proteins. For example,
he attachment of the protein-binding group diphenylcyclohexyl
o a gadolinium(III) chelate via a phosphodiester linkage, like in the
S-325 contrast agent, results in reversible binding of MS-325 to
uman serum albumin in plasma (e.g. Angiomark®, Epix Medical
r MP-2269, Mallinckrodt). The binding to human serum albumin
educes the extravasation of the contrast agent and also leads to a
igh increase in relaxivity [36]. Due to these properties, MS-325
rovides strong, persistent enhancement of blood vessel images
37,38].
Other attempts to design blood pool contrast agents include
ynthesis of macromolecular gadolinium(III) chelates such as
endrimers [39], linear polymers [40], gadofullurenes [41], gado-
anotubes [42], or large protein derivatives obtained by using the
trong interaction present in the avidin–biotin complex [43], as
chematized in Fig. 3. All of these are examples of contrast agents
hat remain conﬁned to the blood vessel space because of their
arge molecular size. Moreover, the presence of a high number of
adolinium complexes for each molecule provides a great increase
n relaxivity of the agent.
A similar approach is under investigation [44–46] with different
endrimeric compounds with varying sizes and properties. These
acromolecules all contain gadolinium complexes on their per-
fery and are prepared employing relatively simple chemistry. The
onodisperse character of dendrimers creates a unique opportu-
ity to introduce dendritic MRI contrast agents into the clinic. For
his approach as well the aim is to obtain high relaxivity and a
rolonged vascular retention time given the large size of dendritic
olecules (e.g. Gadomer®, Schering) [47].
Other polymers derivatized with stable gadolinium complexes
ave also been studied for their speciﬁc clinical applica-
ions and developed with the aim of obtaining molecules
ith extremely high relaxivity. For example the gadolinium-
ased polymers, gadolinium diethylenetriaminepentaacetic acid
DTPA)-co-1,6-diaminohexane (NC 22181) and Gd-DTPA-co-alpha,
mega-diamino-polyethylene glycol(1450) (NC-66368), were for-
ulated at a concentration of 80 mmol/L gadolinium and tested for
se in lymphography in an animal model. Both compounds showed
peciﬁc accumulation in the popliteal nodes of animal models after
ubcutaneous administration in the hind paw and were visualized
sing MRI [48].
Gadolinium-containing metallofullurenes, or gadofullurenes,
ave been proposed as a new generation of higher performance
ontrast agents for MRI [49–52]. The conﬁnement of a Gd(III) ion
ithin the fullerene cage prevents dissociation of the metal ion in
ivo. Speciﬁcally, derivatized Gd@C60 nanoscale materials (1.0 nm
iameter) offer new nanoscale paradigms for the design of high
erformance MRI contrast agent probes up to 20 times more effec-
ive than current clinical contrast agents [51]. In addition, in vivo
iodistribution studies of the water-soluble Gd@C60 derivative
ave shown decreased uptake by the reticuloendothelial system
RES) and high-level clearance through the urinary system [52].non-covalent interactions between high molecular weight molecules such as pro-
tein or polymers and monomeric Gd(III) complexes; (d) supramolecular aggregates
(micelles and liposomes) obtained by co-assembling of amphiphilic gadolinium
complexes and one or more surfactants.
Another successful example of macromolecular systems is
nanotubes. With their nanoscalar, superparamagnetic Gd(III) ion
clusters (1 × 5 nm) conﬁned within ultrashort (20–80 nm) single-
walled carbon nanotube capsules, and their extremely high
relaxivity, gadonanotubes are very effective T1 agents. At 1.5 T,
37 ◦C, and pH 6.5, the r1 relaxivity (ca. 180 mM−1 s−1 per Gd(III)
ion) of gadonanotubes is 40 times greater than any current
gadolinium-based clinical agent [42]. Carbon nanotubes non-
covalently functionalized by amphiphilic Gd chelates are powerful
T1 and T2 MRI contrast agents [53]. The r1 values are particularly
high showing a strong dependence on the Gd complex concen-
tration, particularly at low ﬁeld. The proton relaxivities measured
at 20 MHz with 0.1 and 0.05 mM GdL concentrations are 34.5 and
50.3 mM−1 s−1, respectively.
A new approach has seen the use of macromolecular systems
obtained by derivatizing the gadolinium complex with biotin. A
biotinylated compound is associated to the protein avidin giving
a macromolecular stable adduct containing four gadolinium com-
plexes. This approach has been also used to develop target selective
MRI contrast agents in which the supramolecular adduct is deliv-
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red on tumour cells endowed with avidin receptors [54]. Several
ystems based on the avidin–biotin recognition pathway have been
ecently considered as MRI probes. Bhujwalla and co-workers [55]
ave applied a two component Gd(III)-based avidin–biotin system
or the visualization of HER-2 receptors in an experimental mouse
odel of breast carcinoma. Their approach consisted of targeting
he extracellular domain of the receptors by means of a biotinylated
ntibody. After clearance of the unbound antibody, Gd(III)-labelled
vidin is administered and binds to the biotinylated antibody with
igh afﬁnity. The route based on the formation of non-covalent
dducts may have several advantages, in particular those concern-
ng accessibility and elimination pathways, compared to the use of
acromolecular systems bearing covalent bound Gd(III) chelates.
similar non-covalent approach to prepare other macromolecular
ystems has been followed by using cyclodextrin and its organic
igands [56].
. Micelles and liposomes
Micelles and liposomes are supramolecular aggregates (Fig. 4)
btained by spontaneous assembling in aqueous solution of
mphiphilic molecules consisting of a hydrophobic and a
ydrophilic moiety. The major forces that direct the self-assembly of
mphiphilic molecules into well-deﬁned structures in water derive
rom the hydrophobic associative interactions of the tails and the
epulsive interactions between the hydrophilic head-groups [57].
here is a wide variability in both the hydrophobic and hydrophilic
oieties of amphiphilic molecules. The hydrophobic part can vary
n length and can consist of multiple chains, creating different
atios between the size of the hydrophobic and hydrophilic parts.oreover, the size and charge of the polar head-group can vary,
ividing these molecules into ionic (anionic or cationic) or non-
onic amphiphiles. Ninham and co-workers developed an empirical
odel based on a surfactant parameter (P) to predict aggregate
ype in solution based on the steric relationship of head-group
ig. 4. Schematic representation of supramolecular aggregates (micelles and
iposomes) obtained by assembling in aqueous solution amphiphilic molecules con-
isting of a hydrophobic and a hydrophilic moiety. More common size and shape of
hese aggregates are also reported.y Reviews 253 (2009) 2193–2213 2197
and side arm size [58]. The surfactant parameter, P = v/al depends
from head-group surface area, the volume and length of the side
chains (a, v and l respectively). A value 0.5 < P < 1 predicts vesicles
and P < 0.5 predicts micelle formation. To favour vesicular aggrega-
tion the head-group surface area (a parameter) should be decreased
or the volume of the hydrophobic moiety (v parameter) should
be increased. These characteristics and other parameters such as
pH, ionic strength, temperature and concentration, determine the
geometry of the aggregate that is formed in aqueous solution and
whether a micelle-like structure (spherical, cylindrical, or ellip-
soidal micelles) or a bilayer-like structure (open bilayers, vesicles,
or liposomes) will be formed.
In more detail, micellar aggregates are characterized by their
unique core–shell architecture, where in an aqueous environment
the hydrophobic fragment of the amphiphilic molecules is segre-
gated from the aqueous exterior to form the inner core, and the
hydrophilic part forms the corona or the outer shell. The forma-
tion of micelles is driven by the decrese of of free energy in the
system because of the removal of hydrophobic fragment from the
aqueous environment and the re-estabilishing of hydrogen bond
network in water. Additional energy gain results from formation of
Van der Waals bonds between hydrophobic moieties in the core of
the formed micelles [59,60]. Micelles size normally varies between
5 and 50–100 nm and ﬁlls the gap between such drug carriers as
individual macromolecules (antibodies, albumin, ﬁnd a dextran)
with the size below 5 nm and nanoparticulates (liposomes, micro-
capsules) with the size ca. 50 nm and up. Important characteristics
of micelles are the concentration where they are formed, i.e., the
critical micellar concentration (cmc), kinetic features such as the
micellar lifetime, and their aggregation number. Cmc is the ﬁrst
identiﬁable physical change in solution-containing surfactants, as
their concentration is increased, and represents the concentration
of a monomeric amphiphile at which micelles appear. Optimal cmc
value should be in a micromolar or low millimolar region.
On the other hand, liposomes are self-enclosed artiﬁcial phos-
pholipid vesicles that vary in size from 50 to 1000 nm. They can
be formed by one (unilamellar) or more concentric lipid bilayers
(multilamellar) with an aqueous phase inside and between the lipid
bilayers [61]. Unilamellar vesicles (UVs) can be divided according
to their size in small (SUV, diameter of 50–150 nm) and large (LUV,
diameter 150–800 nm) liposomes. The length of the hydrophobic
moieties and the presence of unsaturated bonds in the phospholipid
chains are two of the most important parameters that inﬂuence
water permeability (Pw) of liposome membrane. The water per-
meability of liposomes decreases with increasing length of the
phospholipid alkyl chain. In addition the presence of one or more
unsaturations in the hydrocarbon chain reduces the tightness of the
bilayer assembly, thus facilitating the water ﬂux across the bilayer.
Stabilization of the lipid bilayer is often aided by the addition of
cholesterol that also inﬂuences Pw [62].
3.1. Paramagnetic aggregates as T1-agents
Micelles and liposomes have recently drawn much attention
owing to their structural properties can be easily controlled thus
allowing favourable pharmacological characteristics. The biodis-
tribution of micelles and liposomes is highly dependent on their
physicochemical properties such as size, surface charge or mem-
brane composition [63–66]. In the pursuit of different in vivo
delivery purposes, one can easily change the size, charge and sur-
face properties of these carriers simply by adding new ingredients
to the mixture of amphiphilic substances used in their preparation
and/or by changing the preparation methods. However, conven-
tional micelles and liposomes are to a large extent taken-up by
the RES. These properties make supramolecular aggregates excel-
lent candidates as possible carriers of Gd(III)-chelates to enhance
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he contrast efﬁcacy and to change the pharmacokinetic proper-
ies of MRI contrast agents, and in the 1980s the ﬁrst studies on
he use of liposomes as carriers of MRI contrast agents appeared
n the literature [67–69]. There have been two main approaches
t the development of liposomal contrast agents: in the ﬁrst one,
ontrast agents are entrapped within the internal aqueous space of
iposomes [67]; in the second approach, lipophilic contrast agents
re incorporated in the lipid bilayer of the liposome [68,69]. Clas-
ical gadolinium complexes such as Gd-DTPA, Gd-DTPA-BMA and
d-HPDO3A have been loaded within the internal aqueous space of
ipid vesicles: the main target for such supramolecular aggregates is
he liver, given the avid accumulation of these aggregates by Kupffer
ells, and the relatively slow clearance of the gadolinium com-
lexes once internalized [70]. While studying blood concentrations
f these aggregates to evaluate the possibility of using these lipo-
omes for MRA application, it was observed that the enhancement
f relaxivity is limited as it is approximately two to ﬁve times lower
ompared to the same concentrations of free gadolinium complexes
n solution. The relaxivity of the entrapped paramagnetic species
ppears to be lowered because of the limited exchange of bulk water
ith the contrast agents [67,71] under these conditions. This slow
xchange is caused by the low permeability of the liposomal mem-
rane to water [72]. Thus the second approach, where a hydrophilic
helating agent is covalently linked to a hydrophobic chain, may
e more effective. In this scheme, the lipid part of the molecule
s anchored in the liposome bilayer while the more hydrophilic
adolinium complex is localized on the liposome surface [73,74].
everal chelating probes of this type have been developed for
iposome membrane incorporation studies: DTPA-PE [75], DTPA-
A [76], amphiphilic acylated paramagnetic complexes of Mn and
d [70]. This approach results in an improved ionic relaxivity of
he metal compared to the approach of encapsulating the para-
agnetic molecules in the aqueous interior liposomial space, and
ompared with low molecular weight complexes [77]. All the above
eported macromolecular contrast agents have been also deriva-
ized by using reporter molecules in order to have target selctive
ontrast agents and some of them have shown interesting prop-
rties for their high relaxivity, biodistribution proﬁle and target
electivity.
.2. Relaxivity of supramolecular contrast agents
The NMRD proﬁle of supramolecular contrast agents shows a
ypical peak at higher frequencies, in agreement with the increase
n the rotational correlation times as compared with low molecular
eight Gd(III) chelates. This means that, at clinically relevant ﬁeld
trengths, these contrast agents have the highest gadolinium relax-
vity. Furthermore, the amount of Gd(III) complexes per particle is
igh (varying from 50 atoms for small micelles to several hundred or
housand of atoms for liposomes). This enhances the total relaxivity
er contrast agent particle enormously. As for classical gadolinium
omplexes, the most important parameters for understanding the
elaxivity of supramolecular contrast agents are the rotational cor-
elation time R, the coordination number, q, the exchange rate M
nd the electronic relaxation time TiE.
The rotational correlation time R is strictly related to the size
nd to the rigidity of the investigated system. A lengthened rota-
ional correlation time R can be achieved by incorporating the
d(III)-complex into the liposomal membrane: this structural orga-
ization reduces the molecular tumbling of the contrast agent thus
ncreasing R. For the analysis of the longitudinal 17O and 1H relax-
tion rates of the aggregates, the Solomon–Bloembergen–Morgan
odel, modiﬁed according to the Lipari–Szabo approach should be
sed [78,79]. According to the Lipari–Szabo approach, the modu-
ation of the interaction that causes relaxation is the result of two
tatistically independent motions: a rapid local motion of the Gd(III)y Reviews 253 (2009) 2193–2213
complex, with a local rotational correlation time l, and a slower
global motion of the entire micellar aggregate, with a global rota-
tional correlation time g. The degree of spatial restriction of the
local motion with regard to the global rotation is given by an addi-
tional model-free parameter, S2. For a totally free internal motion
S2 = 0, while for a local motion that is exclusively correlated to the
global motion S2 = 1. Both the global and the local rotational corre-
lation times are inﬂuenced by the length and by the hydrophobicity
of the side chain in the amphiphilic gadolinium complex.
The coordination number, q, and the exchange rate, M, deter-
mine the amount of water molecules that can effectively coordinate
the Gd(III) ion and thereby increase the relaxation rate T1M. In
micellar structures the gadolinium complexes are entirely exposed
on the external surface of the aggregate, while in liposomes gadolin-
ium complexes are distributed between the inner and the outer
compartment of the liposomes. The number of paramagnetic com-
plex molecules embedded in the inner and outer layers of the
liposomes could be different, and two different contributions aris-
ing respectively from the complexes in the inner and in the outer
layers have to be considered. If the water exchange rate through
the membrane is very slow, the main relaxation effect is expected
to be due to the complex in the outer layer [51,67]. On the con-
trary, if this water exchange is extremely fast, complexes in the
inner and in the outer layer will both contribute to the observed
paramagnetic relaxation rate. The water exchange rate through
the membrane is highly dependent on the permeability [72]. The
more permeable the membrane, the better is the water ﬂux across
the bilayer and the higher the relaxivity [67]. Furthermore, the
exchange with external bulk water can be improved by using
smaller liposomes. The reduction in relaxivity with the use of
large liposomes might be attributed to the reduced surface area-
to-volume ratio and the presence of multilamellar bilayers, which
slow down the water exchange between interior and exterior
of the liposome [67,71]. This implies that in terms of relaxation
properties, an optimal formulation would be liposomes of small
size with a permeable bilayer. Unfortunately, permeable liposomes
usually are less stable in serum than liposomes with more rigid
bilayer.
4. Supramolecular aggregates containing lipophilic Gd(III)
complexes as MRI contrast agents
Contrast agents based on supramolecular aggregates reported
in literature can be divided into at least three categories: in the
ﬁrst one, aggregates are obtained directly by the self-assembly of
an amphiphilic chelating agent; in the second one, aggregates are
obtained by mixing a synthetic amphiphilic chelating agent with
one or more commercial phospholipids; in the third example, the
formulations based on the self-assembly of polymeric amphiphiles
functionalized with the contrast agent.
4.1. Self-assembling aggregates of amphiphilic Gd(III) complexes
Amphiphilic gadolinium complexes are represented by a chelat-
ing agent covalently bound to a hydrophobic moiety such as a long
alkyl chain or an organic molecule that promotes the aggregation
process in a water-based solution. The chelating agent should com-
plex the gadolinium ion with high stability. Generally, the kind
of aggregate obtained by self-assembly of amphiphilic gadolin-
ium complexes are micelles. In micelles, the Gd(III) complexes are
exposed to the hydrophilic exterior space; therefore, there is easy
access of the bulk water to the paramagnetic center.
Most of the amphiphilic Gd(III) complexes are composed of a
gadolinium complex covalently bound to one or more alkylic chains.
The structural properties of the hydrophobic chain such as its length
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nd its nature can inﬂuence the stability, the size and the aggrega-
ion number of monomers in the micelle. Moreover, the relaxivity
ehaviour of micelles can dramatically change as a function of the
ydrophobic moiety.
Several studies were carried out on amphiphilic chelating agents
n order to determine the most accurate mathematical approach
o study the rotational dynamics of the aggregates, and to jus-
ify the relaxivity values. Between 1999 and 2002, Merbach and
o-workers described the synthesis and relaxometric characteri-
ation of ﬁve potential Gd(III)-based MRI contrast agents which
re capable of micellar self-organization. They mainly differ in the
ength of their side chain, varying between 10 and 18 carbon atoms.
hree of them, 1–3, [Gd(DOTAC10)(H2O)]–, [Gd(DOTAC12)(H2O)]–
nd [Gd(DOTAC14)(H2O)]– are DOTA-like chelates bearing a sim-
le alkyl chain with 10, 12 and 14 carbon atoms. The other two,
–5, [Gd(DOTASAC12)(H2O)] and [Gd(DOTASAC18)(H2O)] have a
OTA chelating unit and a monoamide-dodecyl or a monoamide-
ctadecyl carbon side chain, respectively [80,81]. As stated above,
or the analysis of the longitudinal 17O and 1H relaxation rates of the
ggregates, the authors used the Solomon–Bloembergen–Morgan
odel, modiﬁed according to the Lipari–Szabo approach. The relax-
vity values of the ﬁve micellar systems are reported in Table 1.
t is interesting to underline that the relaxivity increases with
ncreasing chain length within the series, with the exception of
Gd(DOTASAC18)(H2O)]−. This effect can be explained by the dif-
erent rotational motions (global and local) and by the model-free
arameter S2 of the ﬁve systems. As expected, the global rota-
ional correlation time, g, increases with increasing length of
he side chain (g = 1600, 2220, 2810 ps, for [Gd(DOTAC12)(H2O)]–,
Gd(DOTAC14)(H2O)]–, [Gd(DOTASAC18)(H2O)]–, respectively). On
he other hand, the local motions, that are also inﬂuenced by length
nd the hydrophobicity of the side chain, do not follow the expected
ehaviour: in fact in [Gd(DOTASAC18)(H2O)]− micelles the addi-
ional amide function, prevents strong hydrophobic interactions
etween the long chains and reduces its internal ﬂexibility (short
l value and low S2).
The relaxivity value of the supramolecular aggregate is inﬂu-
nced not only by their hydrophobic moiety, but also by the
helating agent on the head-group. For example, the relaxivity value
trongly increases from 18.0 to 29.2 mM−1 s−1, simple by replac-
ng the DOTA with the PCTA chelating agent [82], notwithstanding
he two monomers Gd-PCTA-[C12] and DOTASAC12 (indicated in
able 1 as 6 and 5, respectively) have the same hydrophobic
hain, the same coordination geometry on the gadolinium ion and
ggregation properties (micelles with a similar critical micellar con-
entration in the 1.5–3.4 × 10−4 M range).
Clearly the micellization of amphiphilic gadolinium complexes
ives rise to a system with slower molecular tumbling respect
o the monomeric complex, but the resulting relaxivity appears
till lower than the expected values as internal motions are faster
han the overall tumbling of the micellar system. Merbach and co-
orkers demonstrated in 2003 that interactions between nearby
aramagnetic centers in micellar systems increase the transverse
lectronic relaxation of the electronic spin of Gd(III) and, therefore,
educe the attainable water proton relaxivity [83]. This drawback
an be removed by diluting the Gd(III) ions with diamagnetic Y(III)
ons in order to increase the distance between the neighbour-
ng Gd(III) ions. This theory was also recently conﬁrmed by Aime
t al. for micellar aggregates obtained by self-assembling of the
d-AATZAC17 amphiphilic gadolinium complex 7. They studied
ow the relaxivity value of micellar aggregates of Gd-AATZAC17
30.0 mM−1 s−1) changes when 98% of the Gd(III) complexes on the
xternal surface of the micelles is replaced by the corresponding
(III) complexes. The result observed was an enhancement in relax-
vity of around 40% over the entire frequency range (41.4 mM−1 s−1)
84].y Reviews 253 (2009) 2193–2213 2199
Very recently, Geraldes et al. reported an “in vitro” character-
ization and “in vivo” animal imaging studies on self-assembling
micelles of Gd-EPTPA-C16 monomer 8. The in vivo results were
compared with the commercially available low molecular mass
Magnevist® [85]. The synthesis and the relaxometric characteriza-
tion of the supramolecular system were previously reported from
the authors [86]. The critical micellar concentration (3 × 10−4 M)
of the amphiphilic [(Gd-EPTPA-C16)(H2O)]2− chelate was deter-
mined by variable-concentration proton relaxivity measurements.
The rotational dynamics of the micelles, analyzed by using the
Lipari–Szabo approach, suggests that micelles formed in aque-
ous solution show considerable ﬂexibility, with a local rotational
correlation time of l = 330 ps and a global rotational correlation
time g = 2100 ps. These values are in good agreement with the
results above described for 1–5 compounds. The in vivo evaluation
of the micellar [Gd(EPTPA-C16)(H2O)]2− compound in Wistar rats
shows a persistent hepatic positive-contrast effect in T1-weighted
images, which is qualitatively similar to that of the clinically estab-
lished Gd(III)-based hepatobiliary agents, Gd-EOB-DTPA [87] and
Gd-BOPTA [88]. The possibility of using this type of micellar com-
pound for imaging disease depends on the degree of stability of the
imaging agent in the body relative to its critical micellar concen-
tration. The amphiphilic gadolinium complexes above described
have only one hydrophobic chain. Critical micellar concentration
of mono-tailed surfactants is usually in the range of 0.1–0.01 mM.
Upon dilution in the blood following injection, these aggregates
may not be sufﬁciently stable and disassemble immediately fol-
lowing administration. Hence, there is a need to ﬁnd a new class of
surfactant molecules able to form more stable micelles with lower
critical micellar concentration values. One of the possible candi-
dates for this role, can be represented by aggregates obtained by
self-assembling of monomers with two or more alkyl chains.
Recently, Paduano et al. reported supramolecular aggregates,
constituted basically by the DTPAGlu moiety bound to a hydropho-
bic double-tail (18 carbon atoms), 9. The amphiphilic molecule
behaves as an anionic surfactant, and is capable of forming aggre-
gates of different sizes and shapes (rodlike micelles, threadlike
micelles, and vesicles) in aqueous solution by varying the method
of preparation and the environmental conditions such as pH and
ionic strength. A micelle-to-vesicle transition was observed by
decreasing the pH value from 7.4 to 3.0; and/or by increasing the
ionic strength. Relaxivity values of Gd-(C18)2DTPAGlu aggregates
at pH 7.4 in the presence and absence of NaCl at physiological
ionic strength were 21.5 and 24.0 mM−1 s−1, respectively [89,90]. An
alternative approach to prepare physiologically stable aggregates
include the use of Gd-labelled polymerized liposomes, prepared
by using a polymerizable amphiphilic Gd–diethylenetriaminepenta
acetic acid (Gd–DTPA) derivative [91]. Liposomes were prepared
from amphiphilic molecules all containing a diacetylene triple
bond in the fatty acyl chains. Then, to increase their stability, the
triple bond-containing lipids were irradiated by UV light to induce
chain–chain polymerization. These systems showed an improved
physical stability, originated from the increased membrane rigidity
and were able to avoid, to some extent, uptake by RES.
In the literature there are few examples of supramolecular
aggregates obtained also by starting from amphiphilc gadolinium
complexes in which the hydrophobic moiety is not represented by
an alkyl chain, but from an organic molecule such as cholesterol.
In 2003 Lattuada et al. reported the synthesis of Gd-DTPA·Chol
10. The relaxivity value in water (27.2 mM−1 s−1), extremely high
compared to the relaxivity of the Gd-DTPA (3.7 mM−1 s−1), is
an indirect evidence of a micellar self-organization of the Gd-
DTPA·Chol [92]. In 2006 Jorgensen et al. synthesized and studied
the relaxivity behaviour of another cholesterol-based gadolinium
lipid Gd-DOTA·Chol 11, in which the chelating agent is represented
by the DOTA. This molecule was designed to be easily embed-
2200 A. Accardo et al. / Coordination Chemistry Reviews 253 (2009) 2193–2213
Table 1
Relaxivity values, r1, at 20 MHz and 25 ◦C, of self-assembling aggregates obtained by amphiphilic Gd(III) complexes.
Prinicipal investigator
and reference
Compound name # Schematic representation of amphiphilic gadolinium complexes r1 (mM−1 s−1)
A.E. Merbach [80,81] Gd-DOTAC10 1 9.3
Gd-DOTAC12 2 17.2
Gd-DOTAC14 3 21.5
Gd-DOTASAC18 4 20.7
Gd-DOTASAC12 5 18.0
C. Glogard [82] Gd-PCTA-[12] 6 29.2
S. Aime [84] Gd-AAZTAC17 7 30.0
E. Tóth [85,86] Gd-EPTPA-C16 8 22.6
L. Paduano [89] Gd-(C18)2DTPAGlu 9 21.5
L. Lattuada [92] Gd-DTPA·Chol 10 27.2
A.D. Jorgensen [93] Gd-DOTA·Chol 11 4.42a
n tho
d
d
t
a
t
o
t
T
ta Compound 11 maintains a monomeric form, and its relaxivity value is lower tha
ed into the membrane of standard cationic liposomes in order to
evelop a liposome cell labelling system, which would be amenable
o labelling a variety of cells, and could serve other purposes such
s delivery of plasmid DNA or other nucleic acid derived therapeu-
ics. The relaxivity of Gd-DOTA·Chol (4.42 mM−1 s−1) is in the same
rder of values of the clinically used Dotarem (5.25 mM−1 s−1),
hus indicating the Gd-DOTA·Chol is unable to self-aggregate [93].
he uncapability of Gd-DOTA·Chol, with respect to Gd-DTPA·Chol,
o self-aggregate can be ascribed to the lack of anionic chargesse presented by compounds that assemble into aggregates, as expected.
on the complex that reduces the amphiphylic character of the
molecule.
4.2. Mixed aggregates of amphiphilic Gd(III) complexesAnother class of supramolecular aggregates containing gadolin-
ium complexes could be obtained by the co-assembling of
amphiphilic gadolinium molecules with one or more commer-
cial surfactants such as phospholipids, non-ionic surfactants or
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holesterol. Classical phospholipids can be divided in saturated
DPPC, DSPC, DSPE) and unsaturated (DOPC, POPC) molecules.
he most common components of phospholipids are phos-
hatidyl choline (PC), phosphatidyl glycerol (PG) and phosphatidyl
thanolamine (PE). Generally, the presence of phospholipids within
he supramolecular aggregate favours the formation of bilayer
tructures such as vesicles or liposomes. One of the ﬁrst examples
f supramolecular aggregates obtained by amphiphilic gadolin-
um complexes mixed to phospholipids was reported in 1992 from
lgavish et al. They synthesized several amphiphilic gadolinium
onomers (1MP-DTTA; 4MP-DTTA; 4MPD-DTTA; BME-DTTA) and
tudied the in vitro relaxometric behaviour and the in vivo prop-
rties of mixed liposomes as potential contrast agents for MRI
f myocardial under-perfusion [77,94–96]. Gd-BME-DTTA gadolin-
um complex, 12, was obtained by conjugating the DTTA chelating
oiety to two long fatty myristoyl chains. Because of its limited
olubility in water, Gd-BME-DTTA complex was incorporated into
gg lecithin liposomes. The median lethal dose (LD50) of liposomal
d-BME-DTTA formulation in mice was of 0.56 ± 0.05 mmol/kg and
o deleterious effects on heart rate, blood pressure, left ventricular
orce and AV conductance in ferret hearts in vivo at the magnetic res-
nance imaging effective dose of 0.05 mmol/kg body weight were
etected. In MRI images, a 1H signal intensity enhancement was
bserved in the following organs in decreasing order of the effect:
eart ≈ spleen > kidney > liver. This enhancement remained stable
or over 3 h in all organs. Moreover, the incorporation of Gd-BME-
TTA in liposomes produced an increase of the in vitro relaxivity
f the contrast agent up to 27.0 mM−1 s−1. In anyway, the relaxiv-
ty of a liposomal Gd-BME-DTTA sample, stored at 4 ◦C, remained
table for over 4 months of observation, but a signiﬁcant decrease
n relaxivity (8.2 mM−1 s−1 after 40 days) was observed in a sample
tored at room temperature. The observed time-dependent reduc-
ion in relaxivity can be possibly attributed to the dissociation of
d-BME-DTTA from the phospholipid bilayer. Thus, liposome sta-
ility and relaxivity properties of the aggregate over the time are
trongly related to the incorporation degree of amphiphilic gadolin-
um complex in the liposome membrane.
At this purpose, recently Gløgård et al. investigated the effect
n the relaxivity of several parameters including the incorpora-
ion degree of the Gd(III) amphiphilic chelates on the membrane
acking. They studied mixed liposomes formulated by using several
hospholipid molecules (DMPC, DPPC, DSPC, DMPG, DPPG, DSPG)
n which two amphiphilic Gd(III)-DO3A derivatives previously syn-
hesized were alternatively introduced [97]. Gd-HDD-DO3A 13 and
d-HHD-DO3A14 (see Table 2) were synthesized by functionalizing
O3A chelating agent with hydroxydodecyl and hydroxyhexadecyl
oieties, respectively. In the different formulations, the amount of
holesterol and the type of Gd(III)-chelate, were varied between
–40 and 1–10% mol/mol, respectively. The incorporation efﬁcacy
eems to be directly correlated to the lipophilic moiety of the
helates. In fact, Gd-HHD-DO3A, with the highest partition (P)
oefﬁcient between 1-octanol and water, was completely incorpo-
ated whereas an incorporation efﬁcacy between 12 and 23% was
bserved for the less lipophilic Gd-HDD-DO3A. Moreover, larger
iposomes showed only a minor positive effect on the incorpora-
ion efﬁcacy, while the cholesterol content has no effect on the
d-chelate loading [98]. In disagree with the expected results, the
elaxivity value decreased with the increase of incorporation degree
f Gd(III) complex. An explanation of this result could be the neg-
tive inﬂuence of the Gd(III)-chelate on the membrane packing in
he sense of creating disorder. A likely impact of this is an increase
n the lateral surface motion on the liposome surface, leading to a
hortening of R for the Gd(III)-chelates and thereby a decrease in
he relaxivity. The same authors also reported on the inﬂuence of
he cholesterol content on the structure and relaxivity of aggregates
btained by Gd-HHD-DO3A molecules [99].y Reviews 253 (2009) 2193–2213 2201
The incorporation degree of amphiphilic gadolinium complexes
in liposomes represents only one of the numerous parameters that
can play an important role in the relaxivity behaviour of lipo-
somes. Strictly related to the incorporation degree is the mobility
degree of the amphiphilic gadolinium complex, which depends
from the length and from the location of the alkylic chains on
the Gd(III) complex. In this contest, Binnemans et al. between
2003 and 2006 reported the synthesis of three different sets
of amphiphilic derivatives of DTPA with alkyl chains of differ-
ent length. The gadolinium(III) complexes of these ligands were
incorporated into mixed aggregates of DPPC phospholipid and
Tween 80 to obtain supramolecular structures. In the ﬁrst set,
the amphiphilic gadolinium complexes are represented by DTPA-
bisamide derivatives with alkyl chains containing 14, 16 and 18
carbon atoms (Gd-DTPA-BC14, Gd-DTPA-BC16 and Gd-DTPA-BC18,
see Table 2, compounds 15–17) [100]. In the second set, the
DTPA-bisamide derivatives were replaced by the DTPA-monoamide
ones (Gd-DTPA-MC12, Gd-DTPA-MC14, Gd-DTPA-MC16 and Gd-
DTPA-MC18, compounds 18–21) [101]. Finally, in the last set the
DTPA-bisamide derivatives were modiﬁed by introducing aromatic
side chain groups (DTPA-BPT; DTPA-BPH and DTPA-BPO, 22–24)
[102]. By comparing the M and R values of the three sets of
aggregates resulted that the relaxivity values of mixed aggregates
incorporating monoamide complexes are higher than aggregates
incorporating bisamide compounds of the same chain length. Both
M and R values of Gd-DTPA-MCn monoamide supramolecular
aggregates are smaller than those of Gd-DTPA-BCn and Gd-DTPA-
BPX. Indeed it is well known that Gd-DTPA derivatives with amide
groups are characterized by a decreased exchange rate of the
coordinated water molecule and that M is related to the num-
ber of amide functions and their substituents [103]. On the other
hand the R values decrease as a consequence of a more efﬁcient
immobilization of the paramagnetic part of the bisamide deriva-
tives caused by the incorporation of both hydrophobic chains into
the micellar or liposomial membrane. These smaller R values
are not followed by a decrease but by an increase in relax-
ivity because of the smaller M values. The immobilization of
bisamide derivatives at eighteen carbon atoms (Gd-DTPA-BC18 and
Gd-DTPA-BPO) inside the supramolecular structure is less effec-
tive, probably because the aliphatic chains of the complex are
longer than the alkyl chains of DPPC, in which it is inserted,
resulting in a relatively high local mobility. The corresponding para-
magnetic aggregates at 14 carbon atoms DTPA-BPT showed the
highest relaxivity, most likely because the optimal length match
between the hydrophobic chains of the DPPC and the amphiphilic
gadolinium complex allowed very efﬁcient packing of the param-
agnetic complex into the aggregate. Mixed micelles incorporating
Gd-DTPA-MC12 amphiphilic monomer show a relaxivity value
(5.0 mM−1 s−1) more similar to its parent compound Gd-DTPA than
the supramolecular aggregtes. It can be explained by comparing
the R values obtained for the complex Gd-DTPA-MC12 (0.105 ns)
in the micellar solution with respect to those of the other com-
plexes of the series (0.91–1.12 ns). This result indicates that this
complex is either very loosely incorporated inside the micellar
membrane or not incorporated at all. It seems that the aliphatic
chain of this complex is too short and the hydrophobic character
of the complex too low to allow efﬁcient incorporation into the
micellar structures. Finally, the same authors studied a new com-
pound (compound 25, Table 2), Gd-DTPA-BC18Aunsat, containing
C C double bond in the two lipophilic chains [104]. The presence
of the unsatured bond, as reported above, increases the ﬂexibil-
ity inside the membrane layers and the water permeability, thus
increasing relaxivity.
The other parameters inﬂuencing the relaxivity are represented
by the membrane composition of aggregates, such as the saturation
level of membrane, the transition phase temperature of phospho-
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Table 2
Relaxivity values, r1, at 20 MHz and 37–39 ◦C, of liposomal aggregates obtained by amphiphilic Gd(III) complexes.
Prinicipal investigator and reference Compound name # Schematic representation of amphiphilic gadolinium complexes r1 (mM−1 s−1)
G.A. Elgavish [77] Gd-BME-DTTA 12 27.0a
C. Gløgård [97] Gd-HDD-DO3A 13 4.6b
Gd-HHD-DO3A 14 9.2b
R.N. Muller [100] Gd-DTPA-BC14 15 13.3
Gd-DTPA-BC16 16 13.3
Gd-DTPA-BC18 17 8.7
R.N. Muller [101] Gd-DTPA-MC12 18 5.0
Gd-DTPA-MC14 19 15.2
Gd-DTPA-MC16 20 16.6
Gd-DTPA-MC18 21 16.6
T.N. Parac-Vogt [102] Gd-DTPA-BPT 22 11.4
Gd-DTPA-BPH 23 9.7
Gd-DTPA-BPO 24 7.3
R.N. Muller [104] Gd-DTPA-BC18Aunsat 25 17.8
H. Tournier [108,109] 26 18.0
27 –
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lipid and the cholesterol content. As above reported, gadolinium
complexes incorporated in liposome bilayer can distribute them
on both sides of the phospholipidic membrane and the two contri-
butions arising respectively from the complexes in the inner and
in the outer layers have to be considered. The two contributions
depend from liposome membrane permeability which is strictly
related to the bilayer composition (saturated or unsaturated phos-
pholipids). Saturated phospholipids present a lower membrane
permeability with respect to the liposome obtained by unsaturated
phospholipids [72,105]. The reason for such a behaviour is due to
the different packing of the hydrophobic chains in the bilayer. The
presence of an unsaturation in the hydrocarbon chain reduces the
tightness of the bilayer assembly, thus facilitating the water ﬂux
across the bilayer and improving the relaxivity. When the lipo-
some membrane permeability is high, the water exchange will
be extremely fast and both the complex in the inner and in the
outer layer will contribute to the observed paramagnetic relax-
ation rate [106]. On the contrary, if the membrane permeability is
low, water exchange rate through the membrane is very slow and
the main relaxation effect will be due to the complex in the outer
layer. This means that the relaxivity of unsaturated lipids will be
higher compared to those obtained by saturated lipids, because of
the higher accessibility of the water. This theory was very recently
conﬁrmed by Muller et al. The authors compared the relaxomet-
ric behaviour of two unilamellar liposomes (DPPC/compound 15 in
Table 2 = 10/1), incorporating Gd(III) amphiphilic complexes either
in their external and internal layers or only at the external one.
Mixed liposomes with the Gd(III) complexes located only in the
external part were successfully obtained by transmetallation of
La(III) by Gd(III) ions of DPPC/La-DTPA-BC14 liposomes. The relax-
ivity of these liposomes (16.98 mM−1 s−1) is increased as compared
to that of the liposomes containing the complex in both sides of the
membrane (9.86 mM−1 s−1), thus indicating the complex located in
the internal layer contributes less to the global relaxivity [107]. The
water permeability (Pw) of liposomes can be also strongly inﬂu-
enced by the incorporation of amphiphilic gadolinium complexes
in the lipid bilayer, as reported by Aime et al. Two liposome for-
mulations (DPPC/DSPE-PEG2000 and POPC/Chol/DSPE-PEG2000)
were selected in order to compare the variation of the Pw factor
between the saturated and unsaturated liposomes. The amphiphilic
complexes utilized for the experiments (26–28 lanthanide com-
plexes, see Table 2), were previously proposed by Lattuada et al.
as a new class of stable blood pool MRI/MRA contrast agents after
incorporation in mixed aggregates [108,109]. The incorporation in
DPPC-based liposomes of La-26 complex, bearing two saturated
C18 chains, did not affect so much the water permeability of the
membrane, while the incorporation of La-27 complex, bearing one
saturated C12 chain for each coordination arm of the chelate, signif-
icantly accelerated the water mobility across the membrane. This
result suggests the incorporation modality adopted by the latter
amphiphile destabilizes the compact packing of the DPPC bilayer.
Instead, when the amphiphilic complexes (26 and 28 complexes)
are incorporated in unsaturated liposomes (POPC-based liposomes)
a stabilization of the aggregate occurs and the water permeability of
the membrane decreases proportionally to the amount of the incor-
porated compound [110]. Another extremely important parameter
inﬂuencing the relaxivity is represented by the transition phase
temperature. Liposome bilayer, which presents a liquid-crystalline
state have a high water exchange rate between the interior and
exterior liposome comparments, allowing bulk water to experi-
ence magnetic interaction with the Gd-chelates located on the
inner surface. On the contrary, liposome bilayer in the solid–gel
state have a low water exchange rate, making the inner surface
chelates less accessible for the bulk water and thereby decreasing
their contribution to the overall relaxivity [77]. On the other hand,
the lateral motion on the liposome surface is about twice as high in
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liquid-crystalline membrane compared to a gel state membrane
111]. This should give rise to a longer ***R for the Gd-chelates
ncorporated into a gel state-membrane with respect to complexes
ncorporated in liquid-crystalline state, thereby increasing their
elaxivity.
The cholesterol introduction in the formulation has always
positive effect on the relaxivity. The inﬂuence of cholesterol
n the liposome membrane is associated to the phase transition
emperature of the latter. With the incorporation of choles-
erol into a solid–gel liposome ﬂuidises the membrane, leading
o increased transmembrane water permeability and hence an
ncreased relaxivity of the Gd-chelates present inside the lipo-
omes. In the liquid-crystalline liposomes the positive effect
bserved upon cholesterol incorporation is most likely related
o an increase in the membrane rigidity. The rotational correla-
ion time (R) of the Gd-chelate is prolonged, without affecting
dversely the conditions of fast water exchange. According to these
onsiderations, the highest relaxivity was obtained for DMPC-
ased liposomes (24–42 mM−1 s−1) compared to the DSPC-ones
20–28 mM−1 s−1). According to Gløgård assumption, Strijkers
t al., veriﬁed that unsaturated-based liposomes (DOPC/DSPE-
EG2000/Gd-DTPABSA) have higher relaxivity with respect to
he saturated-based ones (DSPC/DSPE-PEG2000/Gd-DTPABOA),
nd the adding of cholesterol to the liposome formulation
eads to a further, although smaller, increase of the relaxivity
112].
Moreover, Aime et al. [113], proposed systems based mixed
iposomes in which gadolinium complexes are conjugated to phos-
holipids by a disulﬁde bond, that is sensitive to radical presence:
hen the disulﬁde bond is cleaved upon radical attach the T1-
elaxivity of the system decreases to approach the value for the
ree Gd chelate.
Nowadays, the research is devoted to ﬁnd new multifunctional
iposomes, able to address at the main time two or more objec-
ives, such as pDNA transfection or diagnosis and treatment of
iseases. For example, in the last year Miller et al. reported the
tility of liposomes as bimodal paramagnetic and ﬂuorescent imag-
ng systems both for in vitro cell labelling and in vivo tumour
maging [114]. They synthesized the amphiphilic gadolinium com-
lex Gd-DOTA·DSA (compound 28 in Table 2) and incorporating
t in DOPC/Chol/DSPE-PEG2000 liposomes. A small amount of the
uorescent lipid DOPE-Rhodamine (0.5–1.0 mole%) was also incor-
orated in the liposome formulation in order to obtain ﬂuorescent
ggregates. This method permits to quantify uptake and inter-
alization processes of liposomes into the cell cytosol. Liposomal
urface was modiﬁed with PEG to prolong presence of contrast
iposomes in the body [115]. In fact, surface modiﬁcation with poly-
ers produces changes in biodistribution and body retention of
iposomes [116]. In greater detail, modiﬁcation with PEG is known
o prolong the circulation times upon intravenous administration
f the coated liposomes [117] this is due to the prevention of
he liposomes opsonisation with macrophage-recognizable [118].
iposome formulation was intravenously injected in nude mice in
hich IGROV-1 (human ovarian cancer cells) xenografts were pre-
iously implanted. Post i.v. injection of Gd-liposomes, xenograft
umours were monitored by MRI over a 24 h period. Over this
eriod, a substantial 60% reduction in tumour T1 values compared
o the situation with control liposomes (without Gd) and visi-
ly enhanced tumour image brightness. This outcome suggested
hat liposomal half-life time (t1/2 > 4 h) is long enough to allow
assive targeting to the xenograft tumour by an enhanced perme-
tion and retention (EPR) mechanism due to the porous nature
f the endothelial cell layer [119]. The ﬂuorescence imaging of
umour tissue slices (post-mortem) supported liposome accumu-
ation in intravascular spaces and in surrounding viable tumour
issue.y Reviews 253 (2009) 2193–2213
4.3. Micelles of amphiphilic poly(gadolinium complexes)
polymers
Polymeric micelles can be obtained by self-assembling block-
copolymers consisting of hydrophilic and hydrophobic monomer
units with the length of the hydrophilic block exceeding to
some extent that of the hydrophobic one. If the hydrophilic
block length is high, copolymers exist in water as individual
molecules, while copolymers with very long hydrophobic block
form lamellar structures [120]. In different amphiphilic polymers,
monomer units with different hydrophobicity can be arranged
into two conjugated blocks each consisting of monomers of
the same type (A–B-type copolymers), or can form alternating
blocks with different hydrophobicity (A–B–A-type copolymers).
The hydrophilic copolymers can also represent a backbone chain
to which hydrophobic blocks are attached as side chains (graft
copolymers). Polymeric micelles have recently attracted much
attention as contrast agents in MRI for their more stability with
respect to micelles prepared from conventional surfactants. Usu-
ally, amphiphilic micelle-forming monomers include PEG blocks
(1–15 kDa) as hydrophilic corona forming blocks [121] for its
low toxicity and its capability of shield micelles from biologi-
cally active macromolecules [122]. At the same time, a variety
of monomers may be used to build hydrophobic core-forming
blocks: propylene oxide [123], l-lysine [124], aspartic acid [125],-
benzoyl-l-aspartate [126], -benzyl-l-glutamate [127], spermine
[128], and some others. Some of these hydrophobic-forming blocks
such as poly(lysine) and poly(aspartic acid) are largely employed
in the synthesis of copolymers as MRI contrast agents for the pres-
ence of reactive functions on their side chains for the coupling of
chelating agents. Anyway, only few examples of supramolecolar
aggregates obtained by using gadolinium-containing copolymers
are reported as MRI contrast agents: compounds 30–33 in Table 3.
The low number of proposed compounds yields difﬁcult to take an
appropriate survey of the relationship between their structures and
relaxivities.
An example is represented by the poly(lysine)-based poly-
chelating polymer (Gd-DTPA-PLL-NGPE) (compound 30, Table 3)
proposed by Torchilin et al. in 2000 [115,129]. Gd-DTPA-PLL-NGPE
polymer, an A–B-type copolymer, can be easily incorporated into
liposome membranes by the presence of a phospholipid residue
(NGPE) at one end of the molecule. Each polymeric DTPA-PLL-NGPE
moiety complex about six Gd(III) ions (at least 31% w/w) and is
incorporated in egg lecithin liposomes. The presence of a single-
terminus modiﬁed polymer containing multiple chelating groups
permits to increase the quantity of the carrier-associated reporter
metals, thus increasing the contrast-to-lipid ratio and enhancing
the signal intensity at the same quantity of the liposomal car-
rier. Upon subcutaneous administration, liposomes penetrate the
lymphatics and effectively visualize its elements in correspond-
ing imaging modalities. Liposomes mostly stay within lymph ﬂuid
rather than accumulate in the nodal macrophages (because of
protective effect of surface PEG fragments) and rapidly move via
the lymphatic pathway. They can serve as fast and efﬁcient lym-
phangiographic agents for scintigraphy or MR imaging. Relaxivity
behaviour and the resistance to the phagocytic cells of chelat-
ing polymer-bearing liposomes were improved by incorporation of
amphiphilic PEG into the liposome membrane.
Successively, Yokoyama et al. designed and developed polymeric
micelles of cationic polymers (polyallylamine or protamine) and
several anionic block A–B-type copolymers (PEGx-P(Asp)y) that
bound Gd(III). Polymeric micelles are able to increase the sig-
nal intensity at the targeted site and to lower, at the same time,
the signal intensity in the vasculature space. In fact it is well
known that high concentration of the contrast agent in the vas-
culature space creates a disadvantageous background, since blood
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Table 3
Relaxivity values, r1, at 20 MHz and 25 ◦C, of polymeric aggregates.
Prinicipal investigator
and reference
Compound name # Schematic representation of amphiphilic gadolinium complexes r1 (mM−1 s−1)
V.P. Torchilin [115,129] Gd-DTPA-PLL-NGPE 30 a
M. Yokoyama [130] PEGx-P(Aspy(DTPA-Gd)z) 31 10–11
S.H. Cho [131] PSI-mPEG-C16-DTPA(Gd) 32 b
K.L. Wooley [132] PAA52-b-PMA128-DTPA(Gd) 33 21.2
[115].
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3a Relaxivity values reported as function of liposomal lipid concentration, see Ref.
b Value not reported.
s supplied both to targeted tissues (or organs) and to non-target
nes. PEGx-P(Aspy(DTPA-Gd)z) 31 polymer was obtained by cou-
ling of the DTPA(Gd) complexes on the anionic core-forming
lock poly(aspartic acid), previously modiﬁed by the introduction
f an ethylenediamine group [130]. This polymeric micelle-type
RI contrast agent changes relaxivity upon micelle formation and
esgregation: Gd(III)-binding block copolymer alone showed high
elaxivity values from 10 to 11 mM−1 s−1, while polymeric micelles
xhibited low relaxivity values from 2.1 to 3.6 mM−1 s−1. The differ-
nt relaxivity values can be ascribed to the different exposition to
he water of the Gd(III) complexes in the two macromolecular sys-
ems. In polymeric micelles Gd(III) complexes are less accessible to
ater molecules because of their location in the inner core of the
icelles.
Another example of polymeric micelle-type MRI contrast agent
as proposed by Cho et al. Aggregates were obtained by self-
ssembling of PSI-mPEG-C16-(DTPA-Gd), (see Table 3, compound
2) a A–B–A-type polymeric compound prepared by conjugating ahydrophilic methoxy-poly(ethylene glycol) (mPEG), a hydrophobic
group (C16) and a gadolinium complex (DTPA-Gd) to a biodegrad-
able polymer (PSI). In vitro, the prepared micelles showed the
enhancement of MRI contrast over ﬁve times of commercially avail-
able Omniscan® [131].
Alternatively to the polymeric aggregates above reported,
obtained by self-assembling of polychelating polymers, Turner et
al. proposed a procedure in which gadolinium complexes are cova-
lently bound on the external surface of the polymeric aggregate
only after the assembling process. The authors developed shell-
crosslinked knedel-like nanoparticles (SCKs) as the scaffolding
from which to produce contrast-enhancing agents. SCKs are self-
assembled core–shell materials, originating from amphiphilic block
copolymer micelles that are covalently stabilized by a crosslinking
reaction. The SCKs were prepared from the aqueous assembly of
a diblock copolymer, PAA52-b-PMA128, and crosslinking the resul-
tant micellar structure throughout the shell layer [132]. After
the assembling, PAA52-b-PMA128-DTPA(Gd), 33 was obtained by
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unctionalizing SCK nanoparticles by DTPA chelating agent. Hydro-
ynamic diameter and aggregation number of amphiphilic block
opolymer chains per SCK were 40 nm and 160, respectively.
lthough the low yield of functionalization reaction (21% and 510
d(III) complexes per nanoparticles), due to the steric hindrance of
he two reactants, the relaxivity value per SCK nanoparticle was of
0,800 at 25 ◦C (21.2 mM−1 s−1 per Gd ion).
. Supramolecular aggregates derivatized with peptides or
ntibodies as target selective MRI contrast agents
All the above reported micelles and liposomes have been devel-
ped with the aim to increase the relaxivity of each gadolinium
tom present in the supramolecular aggregates; moreover the high
umber of gadolinium complexes for each aggregate enhances
he contrast efﬁcacy of these systems, that are also character-
zed by peculiar pharmacokinetic properties and biodistribution
ehaviour. Anyway, a challenge in diagnosis is the non-invasive
etection of molecular markers of diseases in order to identify
nd visualize them in an early stage and to be able to follow the
ffect of therapy. Speciﬁc information on molecular markers can
e obtained with the use of targeted contrast agents, which are
irected to a molecular entity of interest, e.g. endothelial cells
urface receptors that are overexpressed as a consequence of a dis-
ase process. The labelling of gadolinium-containing micelles and
iposomes with bioactive molecules such as antibodies and pep-
ides combines together the high relaxivity of the supramolecular
ggregate with the target selectivity due to the presence of the
ioactive moiety. Several gadolinium-based supramolecular aggre-
ates derivatized with peptides or antibodies are also modiﬁed
ith the introduction of a ﬂuorescent probe to have a bi-modal
etection system and thus conﬁrming their in vitro target selec-
ivity by ﬂuorescence techniques. Different synthetic procedures
ave been developed to introduce the bioactive molecule on the
xternal surface of the supramolecular aggregate [62]. The choice
f synthetic strategy depends on whether coupling is performed
efore or after assembly of the supramolecular aggregate. The obvi-
us goal of each approach is to achieve high coupling efﬁciency, but
ith the ligand retaining full binding afﬁnity for its target receptor.
he coupling of a ligand after the aggregate has been assembled
nvolves the introduction of suitable activated functional groups
nto the terminus of one of the aggregate components. Activated
unctional groups must be compatible with the aggregation process
nd should remain available on the aggregate surface for efﬁcient
hemical ligation of the bioactive ligand. As schematized in Fig. 5a,
n example of this approach consists in the preparation of lipo-
omes or micelles containing a DSPE-PEG monomer derivatized
ith a N-maleimido function on the distal end of the DSPE-PEG
onomer; after aggregate formation the externally exposed N-
aleimido function reacts with the bioactive molecule, according
o the sulphydryl-maleimide coupling method, to give the labelled
upramolecular aggregate. Another example with this approach
s based on the obtainment of biotinylated aggregates using a
iotinylated liphophilic monomer in the surfactant mixture; in a
wo-steps process the biotinylated supramolecular aggregates react
ith avidin and then with the biotinylated peptide or antibody giv-
ng a non-covalently labelled compound (Fig. 5b). This strategy has
roven to be particularly successful for the coupling of large ligands
uch as monoclonal antibodies.
The coupling of a bioactive ligand to an aggregate component
efore aggregation is, in principle, chemically less complicate, but
as the disadvantage that, at least in the case of liposomes, fol-
owing ﬁnal assembly of the aggregate a fraction of the conjugated
ioactive ligand remains entrapped in the interior region and is
ot more available for receptor binding. This labelling procedure,y Reviews 253 (2009) 2193–2213
based on the use of amphiphilic peptides that assemble together
with amphiphilic gadolinium complexes in the peptide labelled
supramolecular aggregates, is schematized in Fig. 5c.
In this chapter, micelles and liposomes based on lipophilic
gadolinium complexes and externally derivatized with antibodies
and peptides acting as target-speciﬁc contrast agents in MRI will be
described.
5.1. Supramolecular aggregates based on lipophilic gadolinium
complexes and derivatized with antibodies
As stated above, liposomes have been studied extensively
during the last two decades as drug carrier vehicles. For this
purpose, they have been optimized in terms of their stability,
circulation time in vivo, and membrane composition. Liposomes
are based on biocompatible natural or synthetic amphiphilic
lipids, they can be sized to a deﬁned diameter in the range of
50–500 nm, and can also be coated with polymers to increase
their stability and prolong their in vivo half-life. Mulder et al. [29]
developed pegylated paramagnetic liposomes, immuno-liposomes,
composed by Gd-DTPA-bis(stearylamide), cholesterol, DOPC and
N-maleimide-DSPE-PEG2000 phospholipids, and derivatized with
antibody molecules coupled to the distal end of the PEG chains. The
chosen antibody is able to detect E-selectin expression on human
umbilical vein endothelial cells, this is an attractive model for recep-
tor expression on endothelial cells, since E-selectin level can be
regulated by TNF and represents a model system for a variety of
endothelial cell surface receptors that are of physiological and ther-
apeutic interest, including v3 integrins and VEGF receptors. In
vitro MRI experiments on pellets gave excellent results in terms of
selectivity: the T1-weighted image of pellets containing 106 TNF
treated human umbilical vein endothelial cells, incubated with the
E-selectinAB-liposomes had a much higher signal intensity than
that of control systems, due to a large shortening of T1 in this system.
The same authors described, very recently, the use of pegy-
lated, ﬂuorescent and paramagnetic micelles (immuno-micelles)
for imaging of macrophages in atherosclerotic plaques [133].
Micelles were obtained by combining together Gd-DTPA-BC18,
DSPE-PEG2000 and N-maleimide-DSPE-PEG2000 phospholipids;
macrophage scavenger receptor (MSR)-speciﬁc antibodies were
conjugated to micelles through N-maleimide function. The abdom-
inal aortas of atherosclerotic apolipoprotein E knockout (apoE-KO)
mice were imaged with T1-weighted high-resolution MRI before
and 24 h after intravenous administration of the micellar contrast
agent. Pronounced signal enhancement was observed for apoE-KO
mice that were injected with MSR-targeted micelles, while the aor-
tic vessel wall of mice injected with non-targeted micelles showed
little signal enhancement, thus demonstrating that macrophages in
apo-E-KO mice can be effectively and speciﬁcally detected by MRI
upon administration of a pegylated micellar gadolinium contrast
agent.
A different approach in preparing immuno-micelles was used by
the same authors [92,134–137]: they obtained mixed micelles com-
bining the amphiphilic gadolinium complex, Gd-DOTA-C16, the
POPC phospholipids and the Tween 80 surfactant, moreover a lit-
tle amount of DPPE-biotin was added to have biotinylated micelles.
Immuno-micelles are obtained by adding, ﬁrst, a speciﬁc amount of
avidin to the biotinylated micelles and, then, the biotinylated anti-
bodies. Micelles were characterized for their size (80–90 nm) their
relaxivity (25–33 mM−1 s−1 per Gd ion) and number of gadolin-
ium atoms (3500–4000). They were used for ex vivo images [134]
and in vivo experiments [135] to detect atherosclerosis, target-
ing macrophage scavenger receptors. Both studies conﬁrmed that
this kind of immuno-micelles provides excellent validated in vivo
enhancement of atherosclerotic plaques. The enhancement seen is
related to macrophage content of the atherosclerotic vessel area
A. Accardo et al. / Coordination Chemistry Reviews 253 (2009) 2193–2213 2207
Fig. 5. Examples of labelling procedures to introduce the bioactive molecule on the external surface of supramolecular aggregates: according to the ﬁrst procedure (a), a
DSPE-PEG monomer derivatized with a N-maleimido function is incorporated in the mixed aggregate; after aggregate formation the externally exposed N-maleimido function
reacts with the bioactive molecule to give the labelled supramolecular aggregate. In another approach (b) biotinylated aggregates are obtained by using in the surfactant
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sixture a biotin bearing lipophilic tail; successively, in a two-steps process, the b
eptides or antibodies interact in free avidin sites giving a non-covalently labelled
olution of amphiphilic peptides and amphiphilic gadolinium complexes.
maged, as clearly reported in Fig. 6, thus these immuno-micelles
ay aid in detection, by MRI, of high macrophage content associ-
ted with vulnerable plaque.
The same approach based on biotin–avidin afﬁnity interac-
ion has been used by Li and co-workers in their pioneering
ork on immuno-liposomes. They prepared polymerized vesi-
les of 300–50 nm in diameter by UV irradiation of a mixture of
adolinium-DTPA polymerizable lipid, a polymerizable biotinilated
ipid and diacetylene phosphatidilcholine ﬁller lipid [92,136,137],
hen derivatized the liposomes with a speciﬁc antibody. Very inter-
sting results have been obtained for in vivo detection of tumour
ngiogenesis targeting the integrinv3 [137]. They used polymer-
zed liposomes derivatized with the LM609 monoclonal antibody
ble to target endothelial v3. As shown in Fig. 7, this approach
rovides enhanced and detailed imaging of rabbit carcinomas by
irectly targeting the gadolinium based contrast agent to the angio-
enic vasculature. In addition, angiogenic “hot spots” not seen by
tandard MRI were detected.
Similar antibody conjugated paramagnetic polymerized lipo-
omes were used to target the intercellular adhesion molecule-1,lated supramolecular aggregates react with the protein avidin, then biotinylated
ound. In the last case, (c) labelled aggregates are obtained assembling a mixture
an endothelial leukocyte receptor on cerebral microvasculature
in experimental autoimmune encephalitis [138]. High-resolution
MRI of mouse brains ex vivo demonstrated that antibody conju-
gated gadolinium based liposomes binding conferred signiﬁcant
enhancement of signal intensity as compared to control images.
5.2. Supramolecular aggregates based on lipophilic gadolinium
complexes and derivatized with peptides
Gadolinium-based paramagnetic supramolecular aggregates
derivatized with bioactive peptides have been essentially devel-
oped in order to have selective contrast agents capable of visualizing
neovascularization and angiogenic processes targeting v3 inte-
grins or tumour proliferization and metastasis targeting cellular
receptors that are overexpressed by cancer cells. Some interest-
ing supramolecular constructs were initially developed by Stupp
and co-workers [30,139] by self-assembly of amphiphile peptide
molecules carrying a DOTA–gadolinium complex. They synthe-
sized, by solid-phase technique peptide amphiphilic molecules
containing the RGD peptide sequences, important for cell adhesion,
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eproduced by permission of PNAS.
r a cysteine rich peptide sequence for cross linking of the self-
ssembled systems, and a DOTA-Gd complex covalently bound to
he N-terminus of the peptide. These amphiphilic molecules self-
ssemble into spherical and ﬁber-like nanostructures, that show
n enhanced T1 relaxation time with a relaxivity increased up
o 22.8 mM−1 s−1 after assembling in supramolecular aggregates
30]. Moreover, van Tilborg recently developed lipid-based bimodal
ontrast agents that enable the detection of apoptotic cells, by func-
ionalizing liposomes with the apoptosis target protein Annexin-5
140].
In next sections we will review supramolecular aggregates
erivatized with RGD peptides or similar sequences capable of tar-
eting v3 integrins and aggregates derivatized with the CCK8
ioactive peptide capable of targeting cholecystokinin receptors
verexpressed on cancer cell membranes.
.2.1. Gadolinium-based paramagnetic supramolecular
ggregates for selective targeting of tumour angiogenesisThe v3 integrin represents an attractive target for molec-
lar imaging of tumour angiogenesis because its expression is
ramatically increased on neovasculature but is not generally
xpressed on quiescent endothelial cells. Schmieder et al. [141] pre-
ared nanoparticles assembling together perﬂuorooctyl-bromided immuno-micelles (a and b), untargeted micelles (c), and Gd-DTPA (d) in ApoE−/−
aorta at the identical anatomic level as the MRI images from the same animal [135].
(PFOB), a surfactant mixture, the lipophilic gadolinium complex
Gd-DTPA-bisoleate, and a little amount of MPB-PEG2000-DSPE;
the nanoparticles were derivatized by conjugating a thiolated
peptidomimetic vitronectin antagonist to the maleimidophenyl
function of MPB-PEG2000-DSPE. The nanoparticles of approxi-
mately 270 nm in diameter, containing ≈300 homing ligands on
their surface and 90,000 Gd ions for particle showed a relaxivity of
about 20 mM−1 s−1 per each gadolinium atom. These nanoparticles
were used to detect and characterize angiogenesis of developing
melanoma xenografts in nude mice (Fig. 8), conﬁrming the use-
fulness of the paramagnetic and target selective nanoparticles in
visualization of very small tumours (≈30 mm3) by increasing spa-
tial resolution and using a small surface coil. Similar liposomes,
conjugated with the v3-speciﬁc RGD peptide attached to PEG
moieties, have been developed by Mulder et al. [119,142]. These
liposomes were used as MRI contrast agents in in vitro and in
vivo studies for detection of v3-integrin and visualization of
proliferating human activated endothelium tumour. In vitro stud-
ies demonstrate that RGD-liposomes associate impressively with
proliferating endothelial cells associated with cancer, they are inter-
nalized by the cells and localized to a perinuclear compartment. In
vivo studies indicate that RGD-liposomes are localized at the rim
of the tumour with a distribution pattern that closely correlates
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Fig. 7. Anti-v3 (LM609) ACPLs confer T1-weighted (T1W) MR signal enhance-
ment of rabbit tumours. (a–e) T1W images of rabbit pre-and 24 h post-targeted
contrast administration. Arrows indicate tumours. (a) Coronal images of rabbit-
bearing tumour in the right thigh muscle. 24 h following LM 609 ACPL
administration, the tumour periphery (arrows), an area of active angiogenesis and
v3 expression (see Fig. 2a), is clearly demarcated. (b) Axial images show a poorly
visible intramuscular tumour pre-contrast. Subsequent to LM609 ACPL administra-
tion, the tumour is more readily discerned. (c) Coronal images of a rabbit with V2
carcinoma implanted subcutaneously. Tumour cannot be distinguished from sur-
rounding normal skin pre-contrast. However, distinct tissue margins are apparent
post-contrast. (d) LM609 ACPLs improve visualization of a subcutaneous tumour.
Hypointense areas represent necrotic tissue (no blood supply). (e) An axial pre-
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Fig. 8. (a) T1-weight MR image (axial view) of an athymic nude mouse before injec-
tion of paramagnetic v3-targeted nanoparticles. Arrow indicates a C32 tumour
that is difﬁcult to detect (Ref.-Gd in 10 cc syringe). (b) Enlarger section of an MR image
5.2.2. Gadolinium-based paramagnetic supramolecularontrast image shows a hyperintense intramuscular tumour with central necrosis.
ost-contrast, LM609 ACPLs reveal angiogenic “hot spots” within viable tumour
137]. Reproduced by permission of Nature Medicine.
ith the position of angiogenic blood vessels in the tumour, which
re found mainly at the rim. Moreover these nanoparticles can be
sed, by MRI techniques, to non-invasively measure the efﬁcacy of
ngiogenesis inhibitors during the course of a therapy [142].
Grifﬁoen co-workers used Anginex, a synthetic 33-mer angio-
tatic peptide that is capable of homing to activated endothelium,
s targeting ligand [143]. Paramagnetic liposomes obtained by co-
ggregation of Gd-DTPA-BC18, maleimide-PEG2000-DSPE, DSPC
nd cholesterol, were derivatized with Anginex by covalently
ttaching the synthetic peptide by sulphydryl-maleimide couplingshowing T1-weight signal enhancement of angiogenic vasculature of early tumours
over 2 h as detected by v3-targeted paramagnetic nanoparticles (BL = baseline
image) [141]. Copyright (2005, John Wiley & Sons, Inc.). Reprinted with permission
of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
to maleimide-PEG-DSPE and studied in vitro on cell cultures and by
MRI of cell pellets. The results indicate that the angiostatic peptide
Anginex is a potent ligand for the targeting of paramagnetic lipo-
somes to activated endothelial cells; in addition the in vitro results
showed a high speciﬁcity of the anginex-conjugated paramagnetic
liposomes for endhotelial cells that was conﬁrmed by MRI.
A different approach was used by Mulder et al. [144] that
developed MRI detectable and targeted quantum dots. Quantum
dots were coated with paramagnetic and pegylated lipids, which
resulted in a relaxivity, r1, of nearly 2000 mM−1 s−1 per quantum
dot. The quantum dots were functionalized by covalently linking
v3-speciﬁc RGD peptides, and the speciﬁcity was assessed and
conﬁrmed on cultured endhothelial cells. For their high relaxiv-
ity and target speciﬁcity these constructs seem excellent contrast
agents for molecular imaging of tumour angiogenesis. Polymeric
constructs have been developed by Ke et al. [145]. They prepared
cyclic RGDdFK target poly(l-glutamic acid)-(Gd-DO3A) conjugate
with a biodegradable cystamine spacer, and evaluated these con-
struct for in vivo detection the angiogenic biomarkerv3-integrin
in neoplastic tissues with T1 mapping by MRI. The targeted conju-
gate showed high speciﬁc binding to human prostate carcinoma
cells with a signiﬁcant decrease of T1 values.aggregates derivatized with CCK8 bioactive peptide
Several supramolecular aggregates derivatized with the CCK8
bioactive peptide on their surface have been developed by Morelli
and Paduano [92,146–149]. Most of these systems have been
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btained by co-assembling two amphiphilic monomers, one con-
aining the gadolinium complex and the other the bioactive peptide
CK8. The presence in the aggregates of two separated monomers
llows the tuning of the ratio between the active components
n order to ﬁnd the right compromise between the number of
eptide targeting molecules on the aggregate surface, and of the
adolinium-chelate complexes. The peptide sequence (Asp-Tyr-
et-Gly-Trp-Met-Asp-Phe-amide, CCK26-33 or CCK8) corresponds
ig. 9. Schematic representation of amphiphilic monomers used to prepare supramolecula
he amino acid sequence of CCK8 peptide is reported by using the one-letter amino acidy Reviews 253 (2009) 2193–2213
to the C-terminal fragment of the cholecystokinin hormone and
provides the binding sequence for the cholecystokinin receptor sub-
types A and B (CCKA-R and CCKB-R) [150]. Overexpression of both of
these receptor subtypes has been demonstrated in certain human
tumours: CCKA-R is overexpressed in pancreatic cancer, and CCKB-R
has been found in small cell lung cancer, colon and gastric cancers,
medullary thyroid carcinomas, astrocitomas and stromal ovarian
tumours [151].
r aggregates derivatized with CCK8 bioactive peptides and DTPAGlu(Gd) complexes.
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The design of the molecules has been developed with the
ain aim to realize supramolecular aggregates (micelles or lipo-
omes) suitable for in vivo use as target selective contrast agents:
ow cmc values of the aggregates in physiological environment,
o toxicity of the entire aggregate and of the single monomers,
nd availability of the bioactive peptide adequately exposed above
he surface. To achieve this goal the design has been gradually
pgraded. In the ﬁrst attempt single-tailed amphiphilic monomers
C18DTPAGlu(Gd) and C18LxCCK8, L = 8-amino-3,6-dioxaoctanoic
cid, x = 2, 5) reported in Fig. 9 (compounds a and b) were pre-
ared. An extensive characterization of these aggregates, with or
ithout complexed Gd(III) ions, has been reported. The monomers
ive mixed spherical micelles with aggregation number around
0–65, and a radius of approximately 40 Å. The peptide seems well
xposed on the micelle surface, particularly in the case of com-
ounds with L5 linker, and, as expected, the relaxivity value is in
he 18–19 mM−1 s−1 range. Unfortunately the aggregate stability,
ndicated by the cmc values, was not high enough to guarantee
ntegrity following dilution, such as after intravenous injection
or the intended in vivo use. To overcome these problems, new
ixed supramolecular adducts in which both the amphiphilic
onomers (second generation monomers) contain as lipophilic
ail, a moiety with two hydrophobic C18 chains were prepared
92]. The two hydrocarbon tails on the same monomer allow for-
ation of very stable aggregates. Moreover monomers bearing
wo hydrophobic tails, do not present hemolytic effects and tox-
city for their higher similarity with membrane phospholipids with
espect to single chain amphiphiles [108]. The aggregates obtained
y assembling the two lipophilic monomers (C18)2DTPAGlu(Gd)
nd (C18)2L5CCK8 in 70:30 ratio (Fig. 9, compounds c and d), are
haracterized by the presence of bilayer structures (open bilay-
rs and liposomes) under conditions of physiologic ionic strength.
he relaxivity value of each gadolinium complex in liposomes
hydrodynamic radius of about 300 Å) was of ∼21.0 mM−1 s−1.
oth the complex in the inner and in the outer layer contribute
o the observed paramagnetic relaxation rate, because of the
igh membrane water permeability due to the high number of
egative charges (two per each DTPAGlu(Gd) complex) in the
ggregate.
Similar results have been obtained for aggregates in which
C18)2L5CCK8 monomer was replaced by (C18)2PEG2000CCK8
ne (Fig. 9, compound e) [152]. In this case, to obtain ade-
uate distancing of the bioactive peptide from the surface of the
upramolecular aggregate, and reduce potential hindrance to its
peciﬁc binding activity, a larger hydrophilic spacer is introduced
etween the peptide N-terminus and the lipophilic tails. Due to its
ize and the well-known empathy for water, poly(ethyleneglycol)
PEG2000 MW = 2000) has been used. The supramolecular aggre-
ated, obtained by mixing togheter the two monomers in 70:30
atio and performing sonication and extrusion steps, are character-
zed by rod-like micelles and closed vesicles. From the structural
oint of view, PEG-containing monomers showed lower tendency
o form liposomes in comparison to L5-containing monomers, also
fter sonication and extrusion processes.
The authors also reported a study in which the structure of
he supramolecular aggregates [148] is inﬂuenced by the ratio
etween the two monomers. Bilayer structures are obtained in
he case of samples containing only DSPE-PEG2000-CCK8 (Fig. 9,
ompound f), or a quantity of (C18)2DTPAGlu(Gd) up to 50%. This
s probably driven by the high energy transferred to the sys-
em by extrusion and sonication procedures. By increasing the
mount of (C18)2DTPAGlu(Gd) in the aggregate, a bilayer–rod-like
icelle transition is observed. The proton relaxivity resulted to be
xactly the same (17.2 mM−1 s−1) for both open bilayers and rod-
ike micelles though in the two cases its value is the result of the
ombination of different local and global contributions.y Reviews 253 (2009) 2193–2213 2211
Many of the above-described systems have also been char-
acterized in vitro and in vivo for their selective binding activity.
For this pourpose the gadolinium atom is replaced with gamma
emitting radioisotope 111In and the aggregate targeting and biodis-
tribution is studied by nuclear medicine experiments. Biological
tests show properties that appear potentially suitable for clinical
applications: (i) signiﬁcantly higher concentration of aggregates in
receptor expressing xenografts relative to controls has been estab-
lished in vivo, suggesting that these aggregates may be utilized
to increase concentration of the gadolinium contrast agent to tis-
sues expressing a speciﬁc receptor target; (ii) slow plasma kinetics
with prolonged half-life and low breakdown of the supramolecular
aggregates, both probably due to the presence of PEG moieties on
the aggregate external surface, that appear useful for maintaining
high blood concentrations of the desired agent.
Finally, new supramolecular aggregates have been developed
[149] based on a new monomer with an upsilon shape (Fig. 9,
compound g, MonY) that contains, in the same molecule, all the
three fundamental tasks that are required: (a) the hydrophobic
moiety that allows the formation of supramolecular aggregates,
(b) the bioactive CCK8 peptide for target recognition, (c) a chelat-
ing agent able to give stable gadolinium complexes. MonY, and
its gadolinium complex MonY(Gd), aggregate in water solution
giving ellipsoidal micelles with the ratio between the micellar
axis of ∼1.7 and the aggregation number Nagg of ∼30. There are
no differences in the aggregation behaviour between MonY and
MonY(Gd) indicating that the presence of metal ions and therefore
the reduction of the net charge does not inﬂuence the aggregation
behaviour. When MonY(Gd) are blended with DOPC, the aggre-
gation behaviour is dictated by the tendency of DOPC in giving
liposomes. Only when the amount of MonY(Gd), is higher than 20%
the coexistence of liposomes and micelles is observed. The thick-
ness d of the bilayer has been valuated by SANS to be ≈35–40 ´˚A,
whereas cryo-TEM images have shown that the diameter of the lipo-
somes ranges between ≈50 and 150 nm. The relaxivity values per
each gadolinium complex of self assembling micelles of MonY(Gd)
and DOPC/MonY(Gd) liposomes (80:20 molar ratio) are 15.03 and
12.7 mM−1 s−1, respectively. Gadolinium complexes in the inner
and in the outer liposomal layers contribute at the same way to
the paramagnetic relaxation rate. In fact, the presence of an unsat-
uration in the hydrocarbon chain of DOPC phospholipids increases
the membrane permeability, thus facilitating the water ﬂux across
the bilayer [106].
6. Conclusions
The in vivo applicability of supramolecular aggregates, such as
micelles and liposomes, containing Gd(III) complexes as contrast
agents in MRI has been well documented. There are several reports
that have approached and optimized issues of stability, relaxivity
and overall safety for in vivo applications. The possibility of using
micellar or liposomal compounds for imaging pourpose depends
on the degree of stability of the imaging agent in the body. Lip-
somes show high stability in biological ﬂuid, while micellar stability
depends by its critical micellar concentration. Physiologically sta-
ble micelles (cmc value in a micromolar or low millimolar region)
can be performed by using either monomers with two or more
alkyl chains, or by polymerizable amphiphilic Gd(III) complexes.
High contrast efﬁcacy can be achieved by designing supramolecu-
lar paramagnetic MR-contrast agents characterized by high rigidity
and good access of bulk water to the paramagnetic center. High
rigidity can be obtained combining together a restricted motion of
the contrast agent of the amphiphilic gadolinium complexes in the
aggregate and a high molecular weight of the particle. These two
effects will normally increase the contrast efﬁcacy by prolonging
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he rotational correlation time of the Gd(III) complex. Fast exchange
etween the water molecule coordinated to the gadolinium ion and
he bulk water can be easily achieved if the Gd(III) complexes are
xposed on the external surface of the aggregate, i.e., micelles; or
n the case of liposomes by using a ﬂuid membrane, which allows
igh water transport across the membrane. The water ﬂux across
he liposome bilayer depends by the length of the phospholipid
lkyl chain and by the presence of unsaturations in the hydrocar-
on chain and by the addition of cholesterol. Future work will also
ave to address how to optimize issues pertaining to the relation-
hip of size and relaxivity. As it stands, the required size of the
ggregates currently utilized that can produce relaxivity changes
n a range suitable for current MRI scanners is fairly large. Issues
oncerning safety for in vivo use of such an approach need further
nvestigation. Applications in which large amounts of high molec-
lar weight contrast media can freely diffuse to selective targets,
uch as for example contrast-enhanced imaging of the vascular sys-
em or molecular targeting of integrins present on endothelial cells,
ave been very successful in animal models and may very well be
uccessful in clinical use. On the other hand, permeability issues
re likely to pose a major impairment for applications of molecu-
ar imaging in tissues where the target receptor or protein is not
reely accessible. Reaching targets on tumour cells for example or
n other tissues with permeability barriers will be very difﬁcult and
dequate concentrations of such aggregates for application in MRI
re likely not to be achieved with currently available technology.
owever, given the rapid rate of progress in this ﬁeld, it is likely
hat optimization of aggregate size and relaxivity will allow one to
iden the range of molecular targeting applications with such an
pproach.
In conclusion, the development of novel MRI contrast agents
ased on supramolecular aggregates derivatized on the external
urface by peptides or antibody should permit to couple high relax-
vity and targeting selectivity on the same particle. Their envisioned
se for the in vivo, non-invasive visualization of molecular mark-
rs should allow one to visualize diseases, for esample cancers,
n the early stages of the transformation towards the malignant
henotype and to improve the quality of life. Moreover, adminis-
ration of the targeted contrast agent should substantially reduce
f deleterious side effects related to the imaging procedure.
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